Chemoprevention of colorectal cancer: Slow, steady progress

Carol A. Burke, MD
Department of Gastroenterology, The Cleveland Clinic

William M. Bauer, MD
Glen Falls Hospital, Glen Falls, New York

Bret Lashner, MD
Department of Gastroenterology, The Cleveland Clinic

Address: Carol A. Burke, MD, Department of Gastroenterology, A30, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; email: burkec1@ccf.org

Dr. Burke has indicated that she has received grant or research support from Merck and Co.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Carol A. Burke, MD
Department of Gastroenterology, The Cleveland Clinic

William M. Bauer, MD
Glen Falls Hospital, Glen Falls, New York

Bret Lashner, MD
Department of Gastroenterology, The Cleveland Clinic

Address: Carol A. Burke, MD, Department of Gastroenterology, A30, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; email: burkec1@ccf.org

Dr. Burke has indicated that she has received grant or research support from Merck and Co.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Carol A. Burke, MD
Department of Gastroenterology, The Cleveland Clinic

William M. Bauer, MD
Glen Falls Hospital, Glen Falls, New York

Bret Lashner, MD
Department of Gastroenterology, The Cleveland Clinic

Address: Carol A. Burke, MD, Department of Gastroenterology, A30, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; email: burkec1@ccf.org

Dr. Burke has indicated that she has received grant or research support from Merck and Co.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.